RealSeq's groundbreaking technology for RNA fragmentomics allows real-time detection of disease dissemination dramatically improving diagnosis and treatment.
Santa Cruz, CA, USA
One Liner
One Liner
RealSeq's groundbreaking technology for RNA fragmentomics allows real-time detection of disease dissemination dramatically improving diagnosis and treatment.
What Problem We are Solving
Problem
Circulating, cell-free RNA (cfRNA) biomarkers are real-time reporters of biological states. They can fundamentally improve diagnosis, progression, and treatment of disease. Only a tiny fraction of the cfRNA population in blood is detectable resulting in biomarker discovery pipelines focusing on <10% of circulating RNAs. The potential of these powerful biological indicators won’t be exploited until the complete complement of cf-RNAs is revealed.
About Us
About Us
RealSeq Biosciences is developing a new generation of RNA fragmentomics-based diagnostics. RealSeq is self-funded with federal grants, revenue generating, and strong customer validation. We are looking for a $1M seed round to allow us to develop the patented RiboMarker diagnostic platform focusing first on Valley Fever, a fungal disease increasing due to climate change. The Valley Fever test validates the platform for future acquisition. RealSeq’s RiboMarkersTM are molecular signatures and real-time reporters for disease and disease dissemination. RiboMarkers are small RNAs that we identified using our novel, patented RealSeqTM sequencing technologies. Our initial RiboMarker program focuses on debilitating fungal diseases which are difficult to detect and where disease dissemination is critical to patient outcomes.
Venture Highlights
Highlights
Milestones:
2 research products and CRO launched 2019
2 NIH Phase II SBIR grants
10 Patents awarded
Projected >$55M Revenue 2026
Customer Highlights:
Extensively used by researchers at biotech and academic institutions
Business Model
Business Model
We target the life science tools market initially- lowest barrier to entry and we are revenue generating selling NGS kits and services direct, through distributors, and partnerships. RealSeq's tool technology is leveraged to develop the RiboMarker platform targeting growing underserved markets such as fungal diagnostics. Our clinical partnerships provide access to patient samples and commercial partnerships will expand RiboMarkers' utility.
Competitive Advantage
Quote
Competitive Advantage RealSeq Biosciences' patented technology platform is agnostic to structural, sequence, and modification variations found in the circulating, cfRNA population. Our technology enables the most comprehensive detection of cfRNA including RNA fragments that can found in any biofluid sample type - blood, saliva, urine. RealSeq reveals the full set of potential cfRNA biomarkers across a vast number of diseases including cancer and infectious disease.
Revenue
Revenue To Date
$1.94M
MRR
N/A
Revenue YTD
N/A
Burn Rate
$87.9K
Users
Total Users
165
Total Users (Past 30 Days)
13
Daily Active Users
N/A
Monthly Active Users
N/A
Total Paying Users
165
MoM Growth Users
N/A
Organic Traffic %
100%
Customer Costs
CAC
N/A
LTV
N/A
Churn
N/A
Margins
N/A
Go-To Market Strategy
Business Strategy
RealSeq life science tools products and services are sold internationally directly and through distribution and OEM/supplier partnerships. The RiboMarker diagnostic platform is commercialized through co-development and licensing agreements. Scientific collaborations and peer reviewed publications provide technology validation and expand customer adoption and retention. Our strategy includes partnering with clinical and scientific opinion leaders in our target markets.
Karius is the dominant company with a cfDNA biomarker-based commercial fungal pathogen LDT. The Karius Test is a static test and incapable of monitoring real-time changes and disease dissemination. There are no other direct competitors with cf-RNA-based technologies for real-time, dynamic detection of infectious disease.
We are open to meeting up to grab a coffee, or just to chat.
We would really enjoy your feedback and insight into our venture and would be happy to discuss anything that you are currently working on to see if we can be of service!
